Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)

NCT02956629 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

282

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated based on review of Phase 2 efficacy data

Conditions

Hepatitis C

Interventions

DRUG: Uprifosbuvir
DRUG: Ruzasvir
DRUG: Ribavirin

Sponsor

Merck Sharp & Dohme LLC